Results 261 to 270 of about 195,924 (307)
Some of the next articles are maybe not open access.
Neoadjuvant therapy improves pCR rate
Nature Reviews Clinical Oncology, 2020openaire +4 more sources
Neoadjuvant Therapy in Esophageal Cancer
Thoracic Surgery Clinics, 2022Locally advanced esophageal cancer has a dismal prognosis. Surgery remains the cornerstone treatment with 5-year survival rates of approximately 12-39%. Rates of local failure and distant metastases are high following surgical resection of locally advanced tumors.
Shirley, Lewis, Jelena, Lukovic
openaire +2 more sources
Neoadjuvant Therapy in Rectal Cancer
Diseases of the Colon & Rectum, 2011The optimal type of neoadjuvant therapy regimen in rectal cancer is contentious.This study aimed to review the impact of neoadjuvant therapy on oncological outcomes and complications (short and long term) in patients undergoing total mesorectal excision for rectal cancer.An electronic search of MEDLINE, PubMed, EMBASE, and the Cochrane Database of ...
Fergal J, Fleming +2 more
openaire +2 more sources
Neoadjuvant Endocrine Therapy Models
2006Neoadjuvant therapy is therapy administered before surgical intervention and while the tumor remains in the breast. It may be given to treat large, locally advanced tumors, with the aim of shrinking them and thus making their surgical excision either simply possible or less radical.
Juliette, Murray +2 more
openaire +2 more sources
Neoadjuvant Therapy Versus Adjuvant Therapy
2012This chapter describes an aspect of study design for oncology clinical trials (and in daily oncology clinical practice), namely, the choice of neoadjuvant therapy, which occurs before surgery, and adjuvant therapy, which occurs after therapy. Neoadjuvant therapy and adjuvant therapy each have specific advantages.
openaire +1 more source
Neoadjuvant Therapy in Pancreatic Cancer
Cancer Investigation, 2007Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. Surgical resection offers the only hope of cure, though the addition of chemoradiation in the adjuvant setting has been shown to improve survival over surgery alone. Many patients are unable to receive adjuvant therapy due to prolonged postoperative recovery.
Roderick M, Quiros +2 more
openaire +2 more sources
Neoadjuvant Therapy of Esophageal Cancer
Surgical Oncology Clinics of North America, 1997Locally advanced esophageal cancer, potentially curable with surgery or radiotherapy-based treatment, has a poor prognosis because of the eventual development of systemic metastatic disease in the majority of patients. Local recurrence of disease after local treatment modalities is equally problematic.
D H, Ilson +3 more
openaire +2 more sources
Seminars in Breast Disease, 2004
The modern era of neoadjuvant endocrine therapy was developed with tamoxifen in the 1980s. Trials showed useful downstaging to avoid mastectomy, but long term results showed that this could be used before but not instead of surgery. Recently neoadjuvant aromatase inhibitors have been shown to be superior to tamoxifen.
openaire +1 more source
The modern era of neoadjuvant endocrine therapy was developed with tamoxifen in the 1980s. Trials showed useful downstaging to avoid mastectomy, but long term results showed that this could be used before but not instead of surgery. Recently neoadjuvant aromatase inhibitors have been shown to be superior to tamoxifen.
openaire +1 more source
Neoadjuvant therapy in cancer treatment
Cancer, 1993Neoadjuvant therapy has come to play an increasingly prominent role in the treatment of cancer. Originally defined as systemic therapy given before local treatment, the concept has been extended to include radiation therapy given before surgery. Potential advantages include improved local and distant control, direct evaluation, and organ-sparing ...
E L, Trimble +7 more
openaire +2 more sources
Neoadjuvant Therapy for Gastric Cancer
Advances in Surgery, 2008Complete surgical resection remains the primary curative treatment option for patients with early stage gastric adenocarcinoma appropriately staged with an adequate lymphadenectomy. Unfortunately, only 40% patients who undergo curative resection at the authors' institution will have early stage (i.e., stage IA or T2N0M0) disease; thus, the majority of ...
Michael G, House, Murray F, Brennan
openaire +2 more sources